Allogene Therapeutics, Inc.

Equities

ALLO

US0197701065

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-14 pm EDT			5-day change	1st Jan Change
2.96 ^USD	+2.07%		+1.72%	-7.79%

03:23pm	Stifel Adjusts Price Target on Allogene Therapeutics to $4.60 From $4.40, Keeps Hold Rating	MT
02:39pm	B. Riley Adjusts Price Target on Allogene Therapeutics to $7 From $10, Keeps Buy Rating	MT

Allogene Therapeutics, Inc. Announces Resignation of Eric Schmidt from Principal Financial Officer and Principal Accounting Officer, Effective from August 2, 2023

June 14, 2023 at 08:04 am EDT

Allogene Therapeutics, Inc. announced the resignation of Eric Schmidt, Ph.D as principal financial officer and principal accounting officer, effective at the close of business on August 2, 2023, to spend more time with his family.

Latest news about Allogene Therapeutics, Inc.

Stifel Adjusts Price Target on Allogene Therapeutics to $4.60 From $4.40, Keeps Hold Rating	09:23am	MT
B. Riley Adjusts Price Target on Allogene Therapeutics to $7 From $10, Keeps Buy Rating	08:39am	MT
Allogene Therapeutics Prices $110 Million Offering	May. 13	MT
Transcript : Allogene Therapeutics, Inc., Q1 2024 Earnings Call, May 13, 2024	May. 13
Allogene Therapeutics Q1 Loss Narrows, Revenue Declines	May. 13	MT
Allogene Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13	CI
Allogene Therapeutics Gets $15 Million Grant from California Institute for Regenerative Medicine for Cancer Drug Development	Apr. 26	MT
Allogene Therapeutics Receives Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma	Apr. 26	CI
Allogene Therapeutics, Inc.(NasdaqGS:ALLO) added to S&P Biotechnology Select Industry Index	Mar. 17	CI
Allogene Therapeutics Files $500 Million Mixed Shelf	Mar. 15	MT
Transcript : Allogene Therapeutics, Inc., Q4 2023 Earnings Call, Mar 14, 2024	Mar. 14
Allogene Therapeutics Q4 Loss Narrows, Revenue Drops	Mar. 14	MT
Allogene Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 14	CI
Allogene Therapeutics to Restate Financial Statements Due to Accounting Adjustments	Feb. 16	MT
Allogene Therapeutics, Inc. Announces Restate Financial Statements for the Years Ended December 31, 2020, 2021 and 2022 and Interim Quarters During 2022 and 2023	Feb. 16	CI
HC Wainwright Adjusts Allogene Therapeutics Price Target to $10 From $12, Maintains Buy Rating	Jan. 19	MT
Transcript : Allogene Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 08:15 AM	Jan. 10
North American Morning Briefing : Boeing Drags -2-	Jan. 08	DJ
B. Riley Adjusts Allogene Therapeutics' PT to $10 From $15 on Heels of Announced Strategic Shift to Focus on New Study for Large B-cell Lymphoma, Keeps Buy Rating	Jan. 05	MT
Allogene Therapeutics to Lay off 22% of Workforce; Partners With Foresight to Develop in Vitro Diagnostic	Jan. 05	MT
Allogene Therapeutics Planning to Cut Roughly 22% of Workforce	Jan. 05	MT
JMP Securities Downgrades Allogene Therapeutics to Market Perform From Market Outperform	Jan. 05	MT
Allogene to cut 22% of its workforce	Jan. 05	RE
Transcript : Allogene Therapeutics, Inc. - Special Call	Jan. 04
Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-Based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma	Jan. 04	CI

Chart Allogene Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on four core programs: Large B-Cell Lymphoma (LBCL), Chronic Lymphocytic Leukemia (CLL), Autoimmune Disease and Renal Cell Carcinoma. It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL and CLL. Its pipeline also includes ALLO-316, ALLO-329 and ALLO-647.

Sector

Biotechnology & Medical Research

Calendar

09:00am - Citizens JMP Life Sciences Conference

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Allogene Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.9 USD

Average target price

9.282 USD

Spread / Average Target

+220.06%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ALLOGENE THERAPEUTICS, INC.	-7.79%	495M
VERTEX PHARMACEUTICALS INCORPORATED	+5.33%	111B
REGENERON PHARMACEUTICALS, INC.	+12.11%	105B
BIONTECH SE	-12.56%	22.34B
ARGENX SE	-3.70%	21.93B
GENMAB A/S	-6.03%	18.59B
WUXI APPTEC CO., LTD.	-35.21%	18.12B
BEIGENE, LTD.	-10.86%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+5.10%	13.7B
SAREPTA THERAPEUTICS, INC.	+37.57%	12.45B

Bio Therapeutic Drugs